Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C Virus 1 year after liver transplantation

Liver Transplantation

Volumn 17, Issue 2, 2011, Pages 178-188

  Manousou, Pinelopi ^a   Dhillon, Amar P ^b   Isgro, Graziela ^a   Calvaruso, Vincenza ^a,c   Luong, T V ^b   Tsochatzis, Emmanuel ^a   Xirouchakis, E ^a   Kalambokis, G ^a   Cross, Timothy J ^a   Rolando, N ^a   O'Beirne, James ^a   Patch, David ^a   Thornburn, D ^a   Burroughs, Andrew K ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PEGINTERFERON; PREDNISOLONE; RIBAVIRIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; AGED; ARTICLE; DECOMPENSATED LIVER CIRRHOSIS; DIGITAL IMAGING; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; KIDNEY DYSFUNCTION; LIVER BIOPSY; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RECURRENT DISEASE; SENSITIVITY AND SPECIFICITY; VENOUS PRESSURE;

ADOLESCENT; ADULT; AGED; BIOPSY; CHILD; COLLAGEN; END STAGE LIVER DISEASE; FEMALE; HEPATIC VEINS; HEPATITIS C; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; KAPLAN-MEIER ESTIMATE; LIVER; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LONDON; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TIME FACTORS; VENOUS PRESSURE; YOUNG ADULT;

EID: 79551486063     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22209     Document Type: Article

References (53)

1. Standish RA, Cholongitas E, Dhillon A, Burroughs AK, Dhillon AP,. An appraisal of the histopathological assessment of liver fibrosis. Gut 2006; 55: 569-578.
2. Armonis A, Patch D, Burroughs A,. Hepatic venous pressure measurement: an old test as a new prognostic marker in cirrhosis? HEPATOLOGY 1997; 25: 245-248.
3. Ripoll C, Banares R, Rincon D, Catalina MV, Lo IO, Salcedo M, et al. Influence of hepatic venous pressure gradient on the prediction of survival of patients with cirrhosis in the MELD Era. HEPATOLOGY 2005; 42: 793-801.
4. Lake JR,. The role of immunosuppression in recurrence of hepatitis C. Liver Transpl 2003; 9 (Suppl): S63-S66.
5. Berenguer M,. Host and donor risk factors before and after liver transplantation that impact HCV recurrence. Liver Transpl 2003; 9 (Suppl): S44-S47.
6. Wiesner RH, Sorrell M, Villamil F,. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9 (Suppl): S1-S9.
7. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR,. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-896.
8. Bedossa P, Dargere D, Paradis V,. Sampling variability of liver fibrosis in chronic hepatitis C. HEPATOLOGY 2003; 38: 1449-1457. (Pubitemid 37466971)
9. Jimenez W, Pares A, Caballeria J, Heredia D, Bruguera M, Torres M, et al. Measurement of fibrosis in needle liver biopsies: evaluation of a colorimetric method. HEPATOLOGY 1985; 5: 815-818.
10. Goodman ZD, Becker RL Jr, Pockros PJ, Afdhal NH,. Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis. HEPATOLOGY 2007; 45: 886-894.
11. Fontana RJ, Goodman ZD, Dienstag JL, Bonkovsky HL, Naishadham D, Sterling RK, et al. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. HEPATOLOGY 2008; 47: 789-798.
12. Calvaruso V, Burroughs AK, Standish R, Manousou P, Grillo F, Leandro G, et al. Computer-assisted image analysis of liver collagen: relationship to Ishak scoring and hepatic venous pressure gradient. HEPATOLOGY 2009; 49: 1236-1244.
13. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699.
14. Cholongitas E, Quaglia A, Samonakis D, Senzolo M, Triantos C, Patch D, et al. Transjugular liver biopsy: how good is it for accurate histological interpretation? Gut 2006; 55: 1789-1794.
15. Crawford AR, Lin XZ, Crawford JM,. The normal adult human liver biopsy: a quantitative reference standard. HEPATOLOGY 1998; 28: 323-331.
16. Datta Gupta S, Hudson M, Burroughs AK, Morris R, Rolles K, Amlot P, et al. Grading of cellular rejection after orthotopic liver transplantation. HEPATOLOGY 1995; 21: 46-57.
17. Samonakis DN, Triantos CK, Thalheimer U, Quaglia A, Leandro G, Teixeira R, et al. Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl 2005; 11: 386-395.
18. Groszmann RJ, Wongcharatrawee S,. The hepatic venous pressure gradient: anything worth doing should be done right. HEPATOLOGY 2004; 39: 280-282.
19. Ripoll C, Groszmann R, Garcia-Tsao G, Grace N, Burroughs A, Planas R, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 2007; 133: 481-488.
20. Garcia-Tsao G, Groszmann RJ, Fisher RL, Conn HO, Atterbury CE, Glickman M,. Portal pressure, presence of gastroesophageal varices and variceal bleeding. HEPATOLOGY 1985; 5: 419-424.
21. Morali GA, Sniderman KW, Deitel KM, Tobe S, Witt-Sullivan H, Simon M, et al. Is sinusoidal portal hypertension a necessary factor for the development of hepatic ascites? J Hepatol 1992; 16: 249-250.
22. Casado M, Bosch J, Garcia-Pagan JC, Bru C, Banares R, Bandi JC, et al. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology 1998; 114: 1296-1303. (Pubitemid 28243916)
23. Kidd IM, Fox JC, Pillay D, Charman H, Griffiths PD, Emery VC,. Provision of prognostic information in immunocompromised patients by routine application of the polymerase chain reaction for cytomegalovirus. Transplantation 1993; 56: 867-871.
24. O'Grady JG, Burroughs A, Hardy P, Elbourne D, Truesdale A,. Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial. Lancet 2002; 360: 1119-1125.
25. Rolles K, Davidson BR, Burroughs AK,. A pilot study of immunosuppressive monotherapy in liver transplantation: tacrolimus versus microemulsified cyclosporin. Transplantation 1999; 68: 1195-1198.
26. Manousou P, Samonakis D, Cholongitas E, Patch D, O'Beirne J, Dhillon AP, et al. Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy. Liver Transpl 2009; 15: 1783-1791.
27. Goodman ZD, Stoddard AM, Bonkovsky HL, Fontana RJ, Ghany MG, Morgan TR, et al. Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial. HEPATOLOGY 2009; 50: 1738-1749.
28. Pape L, Olsson K, Petersen C, von Wasilewski R, Melter M,. Prognostic value of computerized quantification of liver fibrosis in children with biliary atresia. Liver Transpl 2009; 15: 876-882.
29. Blasco A, Forns X, Carrion JA, Garcia-Pagan JC, Gilabert R, Rimola A, et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. HEPATOLOGY 2006; 43: 492-499.
30. Samonakis DN, Cholongitas E, Thalheimer U, Kalambokis G, Quaglia A, Triantos CK, et al. Hepatic venous pressure gradient to assess fibrosis and its progression after liver transplantation for HCV cirrhosis. Liver Transpl 2007; 13: 1305-1311.
31. Kalambokis G, Manousou P, Samonakis D, Grillo F, Dhillon AP, Patch DW, et al. Clinical outcome of HCV-related graft cirrhosis and prognostic value of hepatic venous pressure gradient. Transpl Int 2009; 22: 172-181.
32. Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005; 353: 2254-2261.
33. Bosch J, Abraldes JG, Groszmann R,. Current management of portal hypertension. J Hepatol 2003; 38 (Suppl 1): S54-S68.
34. Berenguer M, Crippin J, Gish R, Bass N, Bostrom A, Netto G, et al. A model to predict severe HCV-related disease following liver transplantation. HEPATOLOGY 2003; 38: 34-41. (Pubitemid 36775793)
35. Gallegos-Orozco JF, Yosephy A, Noble B, Aqel BA, Byrne TJ, Carey EJ, et al. Natural history of post-liver transplantation hepatitis C: A review of factors that may influence its course. Liver Transpl 2009; 15: 1872-1881.
36. Micheloud D, Salcedo M, Banares R, Rincon D, Lorente R, Munoz-Fernandez MA, et al. Serum levels of fibrosis biomarkers measured early after liver transplantation are associated with severe hepatitis C virus recurrence. Transpl Infect Dis 2009; 11: 183-188.
37. Hanouneh IA, Feldstein AE, McCullough AJ, Miller C, Aucejo F, Yerian L, et al. The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl 2008; 14: 1287-1293.
38. Watt KD, Lyden ER, Gulizia JM, McCashland TM,. Recurrent hepatitis C posttransplant: early preservation injury may predict poor outcome. Liver Transpl 2006; 12: 134-139.
39. Everson GT,. Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl 2002; 8 (10 Suppl 1): S19-S27.
40. Papatheodoridis GV, Davies S, Dhillon AP, Teixeira R, Goulis J, Davidson B, et al. The role of different immunosuppression in the long-term histological outcome of HCV reinfection after liver transplantation for HCV cirrhosis. Transplantation 2001; 72: 412-418.
41. Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. HEPATOLOGY 2002; 36: 202-210.
42. Neumann UP, Berg T, Bahra M, Puhl G, Guckelberger O, Langrehr JM, Neuhaus P,. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation 2004; 77: 226-231.
43. Brillanti S, Vivarelli M, De Ruvo N, Aden AA, Camaggi V, D'Errico A, et al. Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transpl 2002; 8: 884-888.
44. Burroughs AK,. Induction immunosuppression for patients who underwent transplantation for cirrhosis caused by hepatitis C? The answer is no! Liver Transpl 2002; 8 (10 Suppl 1): S47-S49.
45. Teixeira R, Pastacaldi S, Davies S, Dhillon AP, Emery VC, Rolles K, et al. The influence of cytomegalovirus viraemia on the outcome of recurrent hepatitis C after liver transplantation. Transplantation 2000; 70: 1454-1458.
46. Chopra KB, Demetris AJ, Blakolmer K, Dvorchik I, Laskus T, Wang LF, et al. Progression of liver fibrosis in patients with chronic hepatitis C after orthotopic liver transplantation. Transplantation 2003; 76: 1487-1491.
47. Burak KW, Kremers WK, Batts KP, Wiesner RH, Rosen CB, Razonable RR, et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002; 8: 362-369.
48. Neumann UP, Berg T, Bahra M, Seehofer D, Langrehr JM, Neuhaus R, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004; 41: 830-836.
49. Wali M, Harrison RF, Gow PJ, Mutimer D,. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002; 51: 248-252.
50. Bahra M, Jacob D, Neumann UP, Spies F, Langrehr JM, Berg T, et al. Influence of donor histology on outcome in patients undergoing transplantation for hepatitis C. Transplantation 2007; 84: 144-148.
51. Zekry A, Whiting P, Crawford DH, Angus PW, Jeffrey GP, Padbury RT, et al. Liver transplantation for HCV-associated liver cirrhosis: predictors of outcomes in a population with significant genotype 3 and 4 distribution. Liver Transpl 2003; 9: 339-347.
52. Sreekumar R, Gonzalez-Koch A, Maor-Kendler Y, Batts K, Moreno-Luna L, Poterucha J, et al. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. HEPATOLOGY 2000; 32: 1125-1130.
53. Bahra M, Neumann UP, Jacob D, Langrehr JM, Berg T, Neuhaus R, Neuhaus P,. Fibrosis progression in hepatitis C positive liver recipients after sustained virologic response to antiviral combination therapy (interferon-ribavirin therapy). Transplantation 2007; 83: 351-353.